Who
James M. Detore
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, CG Oncology; Officer, Proteostasis Therapeutics; Chief Financial Officer, bluebird bio.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Dec 2014
- Last trade
- 15 Apr 2026
- Last filed
- 16 Apr 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Apr 2026filed 16 Apr 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,574 at $0.00 | filing |
| 15 Apr 2026filed 16 Apr 2026 | CGON CG Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,574 at $0.00 | filing |
| 4 Aug 2016filed 8 Aug 2016 | Proteostasis Therapeuticsoption or derivative | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 1 Dec 2014filed 3 Dec 2014 | bluebird biooption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.